At Home Ketamine Therapy vs. In-Clinic: Safety, Efficacy, and What to Know

If you have started researching ketamine, you have almost certainly encountered two very different pitches. One comes from a clinic: a medical suite, an IV line, a nurse in the room, a fixed schedule of infusions. The other arrives in your inbox: a telehealth intake, a lozenge shipped to your door, a video check-in, and a treatment you complete on your own couch. Both are legal. Both are widely used. Both describe themselves as clinically supervised. For anyone weighing at home ketamine therapy against an in-clinic option, the marketing is not much help, because it rarely explains what actually differs and what that difference means for outcomes and for risk.

What Is the Actual Difference Between At-Home and In-Clinic Ketamine?

The most visible difference is the route of administration, and it matters more than it might first appear.

In-clinic ketamine is usually delivered intravenously at a subanesthetic dose, most commonly around 0.5 mg/kg infused over roughly 40 minutes. Because the drug goes directly into the bloodstream, bioavailability is essentially complete and the dose delivered is the dose intended. Some clinics use intramuscular injection instead, which is also highly bioavailable but less precisely controllable once given. A minority offer Spravato (esketamine nasal spray), the only FDA-approved form for treatment-resistant depression, which by federal requirement must be administered in a certified setting with a two-hour observation period.

At-home programs almost always use sublingual ketamine, a lozenge or rapid-dissolving tablet held in the mouth. Sublingual absorption is far less efficient than IV, with bioavailability in the range of roughly 30 percent, compared to approximately 10 to 20 percent for swallowed oral ketamine. That inefficiency is not a flaw so much as a design constraint. Providers compensate with higher milligram doses, but absorption varies with saliva production, how long the lozenge is held, and whether the patient swallows. The practical consequence is that two people taking an identical sublingual dose can end up with meaningfully different blood levels, in a way that does not happen with an infusion.

The second difference is who is in the room. In a clinic, a trained clinician observes you throughout, monitors blood pressure and heart rate, and can intervene immediately. In an at-home model, you are supported remotely by a prescriber and often a coach, and you are typically required to have a designated peer or partner physically present as a monitor. That person is not a clinician.

What Does the Evidence Actually Show for At-Home Ketamine?

Here is where the picture gets more nuanced than either side of the marketing tends to admit.

A large prospective, open-label effectiveness trial of at-home sublingual ketamine delivered through a telehealth platform reported substantial reductions in depression and anxiety symptoms across thousands of patients, alongside a very low rate of serious adverse events. In one widely cited dataset of 11,441 at-home patients, serious adverse events were documented in six people, well under 0.1 percent. A separate retrospective study of off-label at-home sublingual use found roughly a 60 percent reduction in PHQ-9 and GAD-7 scores at four weeks compared with baseline, broadly consistent with the prospective data.

Those are real numbers from peer-reviewed work, and they should not be dismissed. But the design matters as much as the result. These are open-label and observational studies. Patients knew they were receiving ketamine, there was no placebo arm, and the participants were self-selected people who chose and paid for a commercial program. Placebo response in depression trials is substantial, and dissociation makes ketamine notoriously difficult to blind even in randomized settings. What we can say with confidence is that at-home sublingual ketamine, delivered within a screened and monitored program, is associated with meaningful symptom improvement and a low rate of serious harm. What we cannot yet say is how much of that improvement would survive a rigorous placebo-controlled comparison, or how it stacks up head to head against IV ketamine in a randomized trial. That trial has not been done at scale.

In-clinic IV ketamine rests on a longer and more rigorous evidence base, including randomized, placebo-controlled trials in treatment-resistant depression going back nearly two decades. Esketamine has been through the full FDA approval process. This does not automatically make in-clinic care better for every person, but it does mean the two options are not standing on equally firm evidentiary ground, and anyone who tells you otherwise is selling something.

Is At Home Ketamine Therapy Safe?

Ketamine’s acute effects are well characterized. Expect some combination of dissociation, transient elevation in blood pressure and heart rate, nausea, dizziness, and sedation. In appropriately screened patients at subanesthetic doses, these resolve on their own within an hour or two. Serious events are rare in both settings.

The safety difference between the two models is not really about the drug. It is about what happens if something goes wrong, and who is there when it does.

Blood pressure is the clearest example. Ketamine reliably raises it. In a clinic, that spike is measured and managed. At home, it is not measured at all unless you own a cuff and use it. For a healthy 40-year-old with well-controlled vitals, that gap is probably immaterial. For someone with uncontrolled hypertension, a cardiac history, an aneurysm, or elevated intracranial pressure, it is not immaterial at all, and those conditions are precisely why rigorous screening exists. A history of psychosis or mania is a hard stop in both settings. So is active substance use disorder involving ketamine itself.

The other safety variable is the strength of the program wrapped around the medicine. A well-built at-home protocol screens carefully, requires medical records, insists on a present monitor, provides real preparation, checks in after each session, and has a clear escalation path. A poorly built one runs a 12-minute intake, ships lozenges, and calls that supervision. Both exist in the market and both call themselves telehealth ketamine. The safety of at home ketamine therapy is a function of that structure far more than of the route of administration, which is also why comparing the two categories in the abstract is less useful than evaluating the specific provider in front of you.

One more risk deserves naming plainly. Ketamine has genuine abuse potential, and an at-home model puts a supply of a controlled substance in your house. Reputable programs manage this with limited quantities, structured dosing schedules, and monitoring for escalation. It is a reasonable question to ask any provider directly.

What Is the Legal and Regulatory Status in 2026?

At-home ketamine exists in its current form because of a temporary federal accommodation, not a permanent one, and that is worth understanding before you build a treatment plan around it.

Under the Ryan Haight Act of 2008, prescribing a controlled substance generally requires at least one in-person medical evaluation first. During the COVID-19 public health emergency, that requirement was suspended, which is what made remote ketamine prescribing possible at scale. On December 31, 2025, the DEA and HHS issued a fourth temporary extension of those telemedicine flexibilities, allowing DEA-registered practitioners to prescribe Schedule II through V controlled substances by audio-video telehealth without a prior in-person visit, through December 31, 2026.

The agencies have signaled that a permanent framework, likely a special registration pathway for telemedicine prescribers, is intended to replace these extensions. That framework has been proposed but not finalized. Ketamine used for depression is also prescribed off-label; the compound is FDA-approved as an anesthetic, and only esketamine (Spravato) carries approval for treatment-resistant depression. Off-label prescribing is legal and common in psychiatry, but it means the treatment protocols themselves are not FDA-standardized.

The practical takeaway: at-home access is currently legal and currently secure through the end of 2026, and the regulatory environment beyond that is genuinely uncertain. If continuity of care matters to you, ask any prospective provider what their plan is if the rules change.

Which Setting Is Right for You?

The honest answer is that this is a screening question, not a preference question, and it should be answered by a clinician who has reviewed your history.

In-clinic care makes more sense when your medical or psychiatric history introduces real risk that benefits from a clinician in the room. Cardiovascular concerns, a complicated medication list, significant psychiatric comorbidity, severe or acute symptoms, prior adverse reactions to dissociatives, or a living situation without a reliable support person all point toward supervised in-person care. So does severe treatment-resistant depression where you want the strongest available evidence base behind your treatment.

At-home care is a reasonable option when screening is clean, your symptoms are moderate rather than acute, you have a stable and private environment, you have a trustworthy person who can be present, and the barriers to in-clinic access (distance, scheduling, cost, privacy at work) are the actual constraint. For a lot of professionals, privacy is not a minor consideration. A treatment you can complete at home, without a visible pattern of clinic visits, removes a real obstacle.

Whichever setting you choose, one variable predicts outcomes more consistently than anything about the route: the quality of the preparation, support, and integration around the dose. This is covered in more depth in our guide to ketamine therapy preparation and why it matters. If you are still deciding between compounds rather than settings, our comparison of psilocybin and ketamine therapy is a useful starting point, and a full review of medical exclusions is in our guide to psychedelic therapy contraindications.

Questions Worth Asking Any Provider

Before committing to either model, get direct answers to these:

Who reviews my medical history, what are their credentials, and do they request records from my existing physicians? What are your exclusion criteria, and have you ever turned someone away? What happens if my blood pressure spikes or I have a difficult session? How much preparation is included before my first dose, and what does integration support look like after? How is the quantity of medication controlled, and how do you monitor for escalating use? If DEA telehealth rules change, what is your plan for my continuity of care?

A provider who answers these clearly and without defensiveness is demonstrating something more important than any marketing claim about efficacy. A provider who deflects is telling you something too.